COMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder Sells $203,704.93 in Stock

COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) major shareholder George Jay Goldsmith sold 23,881 shares of the business's stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total transaction of $203,704.93. Following the completion of the transaction, the insider now directly owns 3,986,523 shares in the company, valued at approximately $34,005,041.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

George Jay Goldsmith also recently made the following trade(s):

• On Monday, April 1st, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The stock was sold at an average price of $8.96, for a total transaction of $230,720.00.
• On Tuesday, March 12th, George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock. The stock was sold at an average price of $10.58, for a total transaction of $166,529.20.
• On Monday, January 22nd, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The stock was sold at an average price of $8.35, for a total transaction of $215,012.50.
• On Friday, January 19th, George Jay Goldsmith sold 20,205 shares of COMPASS Pathways stock. The stock was sold at an average price of $7.99, for a total transaction of $161,437.95.

COMPASS Pathways Trading Down 1.3 %

CMPS stock traded down $0.11 during mid-day trading on Thursday, reaching $8.42. 291,644 shares of the stock traded hands, compared to its average volume of 694,219. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. COMPASS Pathways plc has a one year low of $5.01 and a one year high of $12.75. The stock has a market capitalization of $521.53 million, a PE ratio of -3.60 and a beta of 2.48. The business has a 50-day moving average price of $10.03 and a two-hundred day moving average price of $8.34.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.16). Equities research analysts expect that COMPASS Pathways plc will post -2.4 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a research note on Thursday. HC Wainwright reaffirmed a "buy" rating and set a $120.00 price target on shares of COMPASS Pathways in a research note on Friday, March 1st. Finally, Morgan Stanley assumed coverage on shares of COMPASS Pathways in a research note on Monday, April 1st. They set an "overweight" rating and a $30.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $47.40.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CMPS. Goldman Sachs Group Inc. grew its holdings in shares of COMPASS Pathways by 122.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 53,587 shares of the company's stock worth $469,000 after purchasing an additional 29,550 shares during the last quarter. Empire Financial Management Company LLC bought a new position in shares of COMPASS Pathways in the fourth quarter worth about $271,000. Barclays PLC grew its holdings in shares of COMPASS Pathways by 21.4% in the fourth quarter. Barclays PLC now owns 501,310 shares of the company's stock worth $4,387,000 after purchasing an additional 88,244 shares during the last quarter. PFM Health Sciences LP grew its holdings in shares of COMPASS Pathways by 540.7% in the fourth quarter. PFM Health Sciences LP now owns 338,761 shares of the company's stock worth $2,964,000 after purchasing an additional 285,890 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC bought a new position in shares of COMPASS Pathways in the fourth quarter worth about $265,000. Institutional investors own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.